MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MDWD
Previous Symbol
CUSIPN/A
Phone972-8932-4010
Debt
Debt-to-Equity RatioN/A
Current Ratio5.47
Quick Ratio5.18
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.50 million
Price / Sales52.15
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.36 per share
Price / Book13.39
Profitability
EPS (Most Recent Fiscal Year)($0.62)
Net Income$-22,140,000.00
Net Margins-477.34%
Return on Equity-400.37%
Return on Assets-35.58%
Miscellaneous
Employees76
Outstanding Shares27,050,000
Market Cap$130.37 million
OptionableNot Optionable
Mediwound (NASDAQ:MDWD) Frequently Asked Questions
What is Mediwound's stock symbol?
Mediwound trades on the NASDAQ under the ticker symbol "MDWD."
How were Mediwound's earnings last quarter?
Mediwound Ltd (NASDAQ:MDWD) issued its earnings results on Tuesday, November, 13th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.19) by $0.08. The biopharmaceutical company had revenue of $0.86 million for the quarter, compared to analysts' expectations of $1.05 million. Mediwound had a negative return on equity of 400.37% and a negative net margin of 477.34%. View Mediwound's Earnings History.
When is Mediwound's next earnings date?
What price target have analysts set for MDWD?
2 equities research analysts have issued 12-month price objectives for Mediwound's shares. Their forecasts range from $11.00 to $14.00. On average, they expect Mediwound's share price to reach $12.50 in the next year. This suggests a possible upside of 159.3% from the stock's current price. View Analyst Price Targets for Mediwound.
What is the consensus analysts' recommendation for Mediwound?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mediwound.
Has Mediwound been receiving favorable news coverage?
News headlines about MDWD stock have been trending somewhat positive on Sunday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mediwound earned a news sentiment score of 1.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Mediwound's key competitors?
Some companies that are related to Mediwound include Foamix Pharmaceuticals (FOMX), Chromadex (CDXC), Natural Alternatives International (NAII), China Jo-Jo Drugstores (CJJD), Pharmacyte Biotech (PMCB), Mannatech (MTEX), GLG Life Tech (GLGLF), Cyanotech (CYAN), FitLife Brands (FTLF), Tauriga Sciences (TAUG), True Drinks (TRUU), Nutra Pharma (NPHC), Entia Biosciences (ERGO), Rock Creek Pharmaceuticals (RCPIQ) and Beleave (BE).
Who are Mediwound's key executives?
Mediwound's management team includes the folowing people:
- Mr. Gal Cohen, Pres & CEO (Age 45)
- Prof. Lior Rosenberg, Co-Founder & Chief Medical Technology Officer (Age 72)
- Mr. Sharon Malka CPA, MBA, Chief Financial & Operation Officer (Age 46)
- Mr. Carsten Henke, Chief Commercial Officer of Europe (Age 52)
- Dr. Ety Klinger, Chief R&D Officer (Age 56)
Who are Mediwound's major shareholders?
Mediwound's stock is owned by a number of of retail and institutional investors. Top institutional investors include Migdal Insurance & Financial Holdings Ltd. (7.86%), Jefferies Group LLC (0.76%), Renaissance Technologies LLC (0.66%), Nexthera Capital LP (0.64%) and Worth Venture Partners LLC (0.18%).
Which institutional investors are buying Mediwound stock?
MDWD stock was purchased by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Nexthera Capital LP, Worth Venture Partners LLC, Renaissance Technologies LLC and Migdal Insurance & Financial Holdings Ltd..
How do I buy shares of Mediwound?
Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mediwound's stock price today?
One share of MDWD stock can currently be purchased for approximately $4.82.
How big of a company is Mediwound?
Mediwound has a market capitalization of $130.37 million and generates $2.50 million in revenue each year. The biopharmaceutical company earns $-22,140,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Mediwound employs 76 workers across the globe.
What is Mediwound's official website?
How can I contact Mediwound?
Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]
MarketBeat Community Rating for Mediwound (NASDAQ MDWD)
MarketBeat's community ratings are surveys of what our community members think about Mediwound and other stocks. Vote "Outperform" if you believe MDWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
